

# Robert Hollis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3061096/publications.pdf>

Version: 2024-02-01

26  
papers

639  
citations

686830

13  
h-index

676716

22  
g-index

33  
all docs

33  
docs citations

33  
times ranked

847  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and molecular changes in ovarian cancer. <i>Cancer Biology and Medicine</i> , 2016, 13, 236-247.	1.4	82
2	Clear cell carcinoma of the ovary: a clinical and molecular perspective. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 605-616.	1.2	79
3	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Over 541-553.	6.3	75
4	Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. <i>Nature Communications</i> , 2020, 11, 4995.	5.8	70
5	Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1647.	1.7	49
6	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2539-2551.	1.0	45
7	High <i>EMSY</i> expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , 2019, 125, 2772-2781.	2.0	28
8	Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1409-1420.	1.1	28
9	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27
10	Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 245.e1-245.e15.	0.7	22
11	Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. <i>Gynecologic Oncology</i> , 2019, 152, 278-285.	0.6	20
12	Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 318-323.	0.6	18
13	Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. <i>Cancers</i> , 2020, 12, 1503.	1.7	17
14	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. <i>British Journal of Cancer</i> , 2022, 127, 1034-1042.	2.9	14
15	Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. <i>BMC Cancer</i> , 2018, 18, 16.	1.1	13
16	Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells. <i>EMBO Journal</i> , 2020, 39, e102166.	3.5	12
17	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020, 32, 442-450.	1.1	10
18	Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. <i>Npj Precision Oncology</i> , 2021, 5, 47.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma. <i>Cancers</i> , 2021, 13, 5839.	1.7	8
20	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. <i>Clinical Cancer Research</i> , 2022, 28, 3546-3556.	3.2	5
21	Abstract 322: High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with superior survival and platinum sensitivity. , 2018, , .		1
22	Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas. <i>Cancer Research</i> , 2019, 79, 749-749.	0.4	1
23	A retrospective study of endocrine therapy in high grade serous ovarian carcinoma. <i>Annals of Oncology</i> , 2017, 28, v338-v339.	0.6	0
24	Molecular stratification of endometrioid ovarian carcinomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5553-5553.	0.8	0
25	Abstract 4161: Integrated analysis of whole exome sequencing and hormone receptor expression data in endometrioid ovarian cancer. , 2020, , .		0
26	367â€¦The use of real-world evidence from the edinburgh ovarian cancer database to explore a data gap in the prima trial. , 2020, , .		0